What is the optimal treatment volume in Hodgkin's disease patients undergoing high-dose chemotherapy and adjuvant radiation therapy?

Radiation Oncology Investigations

Volumn 7, Issue 6, 1999, Pages 353-359

  Mundt, Arno J ^a   Connell, Philip P ^a   Mansur, David B ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Adjuvant radiotherapy; High dose chemotherapy; Hodgkin's disease

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; THIOTEPA;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HODGKIN DISEASE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIATION DOSAGE; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0033378072     PISSN: 10657541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6823(1999)7:6<353::AID-ROI5>3.0.CO;2-8     Document Type: Article

References (33)

1. Yahalom J. Integrating radiotherapy into bone marrow transplantation programs for Hodgkin's disease. Int J Radiat Oncol Biol Phys 1995;33:525-528.
2. Constine LS, Rapoport AP. Hodgkin's disease, bone marrow transplantation, and involved field radiation therapy: coming full circle from 1902 to 1996. Int J Radiat Oncol Biol Phys 1996;36:253-255.
3. Armitage JO, Bierman PJ, Vose JM, Anderson JR, Weisenburger DD, Kessinger A, Reed EC, Vaughn WP, Coccia PF, Purtilo DT. Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease. Am J Med 1991;91:605-611.
4. Jost LM, Widmer L, Honegger HP, Stahel RA. Index of pretreatment intensity predicts outcome of high-dose chemotherapy and autologous progenitor cell transplantation in chemosensitive relapse of Hodgkin's disease. Ann Oncol 1997;8:785-790.
5. Phillips GL, Wolff RH, Herzig RH, Lazarus HM, Fay JW, Lin HS, Shina DC, Glasgow GP, Griffith RC, Lamb CW, Herzig PG. Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 1989;73: 2086-2092.
6. Chopra R, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R, Patterson KG, Goldstone AH. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease: a single center eight-year study of 155 patients. Blood 1993;81:1137-1145.
7. Reece DE, Connors JM, Spinelli JJ, Barnett MJ, Fairey RN, Klingemann HG, Nantel SH, O'Reilly S, Shepard JD, Sutherland H, Voss NJ. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologhous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994;83:1193-1199.
8. Reece DE, Barnett MJ, Shepherd JD, Hogge DE, Klasa RJ, Nantel SH, Sutherland HJ, Klingemann HG, Fairey RN, Voss NJ. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-231) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 1995;86:451-456.
9. Yuen AR, Rosenberg SA, Hoppe RT, Halpern JD, Horning SJ. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997; 89:814-822.
10. Ghalie R, Richman CM, Adler SS, Korenblit AD, Kramer TS, Manson S, Dolce A, Kaizer H. Involved field radiation, fractionated total body irradiation, high dose cyclophosphamide, and autologous bone marrow transplantation in the treatment of malignant lymphomas. Bone Marrow Transplant 1991;8:41-45.
11. Harding M, Selby P, Gore M, Perren T, Treleaven J, Mansi J, Zulian G, Milan S, Meldrum M, Viner C. High-dose chemotherapy and autologous bone marrow transplantation for relapsed and refractory Hodgkin's disease. Eur J Cancer 1992;28A:1396-1400.
12. Carella AM, Congiu AM, Gaozza E, Mazza P, Ricci P, Visani G, Meloni G, Cimino G, Mangoni L, Coser P, Cetto GL, Cimino R, Alessandrino EP, Brusamolino E, Santini G, Tura S, Mandelli F, Rizzoli V, Bernaconi C, Marmont A. High dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report. J Clin Oncol 1988;6:1411-1416.
13. Phillips GL, Reece DE, Barnett MJ, Connor JM, Fay JW, Herzig GP, Herzig RH, Klingemann HG, Shepherd JD, Wolff SN. Allogeneic marrow trnaplantation for refracotry Hodgkin's disease. J Clin Oncol 1989;7: 1039-1045.
14. Jagannath S, Armitage JO, Dicke K, Tucker SL, Velasquez WS, Smith K, Vaughn WP, Kessinger A, Horwitz LJ, Hagemeister FB, McLaughlin P, Cabanillas F, Spitzer G. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1989;7:179-185.
15. Reece DE, Bamett MJ, Connors JM, Fairey RN, Greer JP, Herzig GP, Herzig RH, Klingemann HG, O'Reilly SE, Shepherd JD, Spinelli JJ, Voss NJ, Wolff SN, Phillips GL. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991;9:1871-1879.
16. Lundberg JH, Hansen RM, Chitambar CR, Lawton CA, Gottleib M, Anderson T, Ash RC. Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA-identical and alternative donors. J Clin Oncol 1991;9:1848-1859.
17. Anderson JE, Litzow MR, Appelbaum FR, Schoch G, Fisher LD, Buckner CD, Petersen FB, Crawford SW, Press OW, Sanders JE, Bensinger WI, Martin PJ, Storb R, Sulllivan KM, Hansen JA, Thomas ED. Allogeneic, syngeneic and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol 1993;11:2342-2350.
18. Crump M, Smith AM, Brandwein J, Couture F, Sherer H, Sutton DMC, Scott JG, McCrae J, Murray C, Pantalony D, Sutcliffe SB, Keating A. High-dose etoposide and melphalan, and autologous bone marrow transplantation after chemotherapy in advanced Hodgkin's disease: importance of status at transplant. J Clin Oncol 1993;11:704-711.
19. Yahalom J, Gulati SC, Toia M, Maslak P, McCarron EG, O'Brien JP, Portlock CS, Strauss DJ, Phillips J, Fuks Z. Accelerated hyperfractionated total-lymphoid irradiation, high dose chemotherapy and autologous bone marrow transplantation for refractory and relapsed patients with Hodgkin's disease. J Clin Oncol 1993;11: 1062-1070.
20. Rapaport AP, Rowe JM, Kouides PA, Duerst RA, Abboud CN, Liesveld JL, Packman CH, Eberly M, Sherman M, Tanner MA, Constine LS, DiPresio JF. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. J Clin Oncol 1993;11:2351-2361.
21. Pfrendschuh MG, Rueffer U, Lathan B, Schmitz N, Brosteanu O, Hasenclever D, Haas R, Kirchner H, Koch P, Kuse R, Loeffler M, Diehl V. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's disease study group. J Clin Oncol 1994;12:580-586.
22. Hurd DD, Haake RJ, Lasky LC, Christiansen NP, McGlave PB, Bostrom B, Levine EG, Weisdorf DJ, Kim TH, Petersen BA. Treatment of refractory and relapsed Hodgkin's disease: intensive chemotherapy and autologous bone marrow or peripheral blood stem cell support. Med Pediatr Oncol 1990;18:447-453.
23. Fleury J, Legros M, Colombat P, Cure H, Travade P, Tortochaux J, Dionet C, Chollet P, Linassier C, Lamagnere JP, Biaise D, Viens P, Maraninchi D, Plagne R. High-dose therapy and autologous bone marrow transplantation in first complete or partial remission for poor prognosis Hodgkin's disease. Leuk Lymphoma 1996; 20:259-266.
24. Poen JC, Hoppe RT, Horning S. High-dose therapy and autologous bone marrow transplantation for relapsed/ refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival. Int J Radiat Oncol Biol Phys 1996;36:3-12.
25. Pezner RD, Nademanee A, Niland JC, Vora N, Forman SJ. Involved-field radiation therapy for Hodgkin's disease autologous bone marrow transplantation regimens. Radiother Oncol 1995;34:23-29.
26. Lancet JE, Rapoport AP, Brassachio R, Eberly S, Raubertas RF, Linder T, Muhs A, Duerst RE, Abboud CN, Packman CH, DiPresio JF, Constine LS, Rowe JM, Liesveld JL. Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant 1998;22:265-271.
27. Jones RJ, Piantadosi S, Mann RF, Ambinder RF, Seifter EJ, Vriesendorp HM, Abeloff MD, Burns WH, May WS, Rowley SD, Vogelsang GB, Wagner JE, Wiley JM, Wingard JR, Yeager AM, Saral R, Santos GW. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1990;8:527-537.
28. Mundt AJ, Sibley G, Williams SF, Hallahan D, Nautiyal J, Weichselbaum RR. Patterns of failure after high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease. Int J Radiat Oncol Biol Phys 1995;33:261-270.
29. Yahalom J, Gulati S, Shank B, Clarkson B, Fuks Z. Total lymphoid irradiation, high-dose chemotherapy and autologous bone marrow transplantation for chemotherapy-resistant Hodgkin's disease. Int J Radiat Oncol Biol Phys 1989;17:915-922.
30. Yahalom J, Gulati S. Autologous bone marrow transplantation for refractory or relapsed Hodgkin's disease: the Memorial Sloan-Kettering Cancer Center experience using high-dose chemotherapy with or without hyperfractionated accelerated total lymphoid irradiation. Ann Oncol 1991;2(Suppl 2):67-71.
31. Lee CK, Bloomfield CD, Goldman AI, Nesbit ME, Levitt SH. The therapeutic utility of lung irradiation for Hodgkin's disease patients with large mediastinal masses. Int J Radiat Oncol Biol Phys 1981;7:151-154.
32. Loeffler M, Diehl V, Pfreundshuh M, Ruhl U, Hasenclever D, Nisters-Backes H, Sieber M, Tesch H, Franklin J, Geilen W, Bartels H, Cartoni C, Dolken G, Enzian J, Fuchs R, Gassman W, Gerhartz H, Hagen-Aukamp U, Hiller E, Hinkelbein H, Hinterberger W, Kirchner H, Koch P, Kruger B, Schwarze EW. Dose-response relationship of complementary radiotherapy after four cycles of combination chemotherapy in intermediatestage Hodgkin's disease. J Clin Oncol 1997;15:2275-2287.
33. Yahalom J, Ryu J, Straus DJ, Gaynor JJ, Myers J, Caravelli J, Clarkson BD, Fuks Z. Impact of adjuvant radiation on the patterns and rate of relapse in advancedstage Hodgkin's disease treated with alternating chemotherapy combinations. J Clin Oncol 1991;9: 2193-2201.